STEVENSON, Md., Jan. 30, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Xunlei Limited (Nasdaq:XNET) (“Xunlei” or the “Company”) securities during the period between October 10, 2017, and January 11, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 20, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Xunlei securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that: Xunlei had engaged in an unlawful financial activity; OneCoin was a form of disguised initial coin offering (“ICO”); and Xunlei was engaged in the promotion of an Initial Miner Offering (“IMO”).
According to the complaint, following November 24, 2017 new reports that the Company’s business partner conducted an unlawful ICO, a November 29, 2017 press release announcing an update on its business relationship with Big Data, and a January 12, 2018 issue of a risk alert notice regarding a disguised ICO, the value of Xunlei American Depositary shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Xunlei securities purchased on or after October 10, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 



